DuPont de Nemours (DD) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

06.11.25 15:30 Uhr

Werte in diesem Artikel
Aktien

33,98 EUR -0,49 EUR -1,41%

Indizes

6.720,3 PKT -76,0 PKT -1,12%

For the quarter ended September 2025, DuPont de Nemours (DD) reported revenue of $3.07 billion, down 3.8% over the same period last year. EPS came in at $1.09, compared to $1.18 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $2.63 billion, representing a surprise of +16.94%. The company delivered an EPS surprise of +4.81%, with the consensus EPS estimate being $1.04.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.Here is how DuPont de Nemours performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:Net Sales- IndustrialsCo: $1.8 billion versus $2.1 billion estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +30% change.Net Sales- ElectronicsCo: $1.28 billion compared to the $1.22 billion average estimate based on two analysts. The reported number represents a change of -17.8% year over year.Operating EBITDA- ElectronicsCo: $403 million compared to the $394.86 million average estimate based on two analysts.Operating EBITDA- Corporate & Other: $-28 million compared to the $-34 million average estimate based on two analysts.Operating EBITDA- IndustrialsCo: $465 million versus $515.11 million estimated by two analysts on average.View all Key Company Metrics for DuPont de Nemours here>>>Shares of DuPont de Nemours have returned -49.4% over the past month versus the Zacks S&P 500 composite's +1.3% change. The stock currently has a Zacks Rank #5 (Strong Sell), indicating that it could underperform the broader market in the near term.Zacks' Research Chief Names "Stock Most Likely to Double"Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.This top pick is a little-known satellite-based communications firm. Space is projected to become a trillion dollar industry, and this company's customer base is growing fast. Analysts have forecasted a major revenue breakout in 2025. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Hims & Hers Health, which shot up +209%.Free: See Our Top Stock And 4 Runners UpWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report DuPont de Nemours, Inc. (DD): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks

In eigener Sache

Übrigens: DuPont de Nemours und andere US-Aktien sind bei finanzen.net ZERO sogar bis 23 Uhr handelbar (ohne Ordergebühren, zzgl. Spreads). Jetzt kostenlos Depot eröffnen und Neukunden-Bonus sichern!

Ausgewählte Hebelprodukte auf DuPont de Nemours

Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf DuPont de Nemours

NameHebelKOEmittent
NameHebelKOEmittent
Wer­bung

Quelle: Zacks

Nachrichten zu DuPont de Nemours

Wer­bung

Analysen zu DuPont de Nemours

DatumRatingAnalyst
04.10.2021DuPont de Nemours OverweightJP Morgan Chase & Co.
20.08.2019DowDuPont OutperformCowen and Company, LLC
25.06.2019DowDuPont NeutralMonness, Crespi, Hardt & Co.
10.06.2019DowDuPont OutperformCowen and Company, LLC
06.02.2019DowDuPont Market PerformCowen and Company, LLC
DatumRatingAnalyst
04.10.2021DuPont de Nemours OverweightJP Morgan Chase & Co.
20.08.2019DowDuPont OutperformCowen and Company, LLC
10.06.2019DowDuPont OutperformCowen and Company, LLC
12.10.2018DowDuPont buyDeutsche Bank AG
29.03.2018DowDuPont OutperformBMO Capital Markets
DatumRatingAnalyst
25.06.2019DowDuPont NeutralMonness, Crespi, Hardt & Co.
06.02.2019DowDuPont Market PerformCowen and Company, LLC
12.09.2017DowDuPont NeutralMonness, Crespi, Hardt & Co.
31.05.2017Dow Chemical Market PerformCowen and Company, LLC
26.04.2017DuPont (E I DuPont de Nemours and Sector PerformRBC Capital Markets
DatumRatingAnalyst
05.01.2009Dow Chemical verkaufenEuro am Sonntag
11.04.2007Dow Chemical verkaufenHamburger Sparkasse
03.02.2006Update Rohm and Haas Co.: ReduceUBS
07.07.2005Update Rohm and Haas Co.: SellLongbow

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für DuPont de Nemours nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"
Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"
Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"
mehr Analysen